GNRH1 and posterior cortical atrophy: Buserelin was the first LH-RH agonist introduced to treat advanced PCa outside the US in 1985 [5], and goserelin was the first Food and Drug Administration (FDA)-approved LH-RH agonist in 1989 [6].